Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | HTR2A | P28223 | 3/20 | 0.45 |
| ▸ | HTR2C | P28335 | 3/20 | 0.45 |
| ▸ | HTR2B | P41595 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 5/20 | 0.41 |
| ▸ | GFER | P55789 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20868221 | 0.86 | HTR2A (0.55) | ALDH1A1KDM4EHTR2AHTR2CHTR2B | |
| SCHEMBL21448970 | 0.83 | TRPV1 (0.47) | ALDH1A1KDM4EHTR2AHTR2CHTR2B | |
| SCHEMBL617426 | 0.82 | KDM4E (0.58) | ALDH1A1KDM4EHTR2AHTR2CHTR2B | |
| SCHEMBL731190 | 0.78 | KMT2A (0.50) | ALDH1A1KMT2AMAPTSMN1; SMN2HTT | |
| SCHEMBL20868507 | 0.77 | NCF1 (0.60) | ALDH1A1KDM4EKMT2AACE2KLKB1 | |
| SCHEMBL10233022 | 0.77 | ALDH1A1 (0.51) | ALDH1A1KDM4EKMT2AACE2KLKB1 | |
| SCHEMBL24858705 | 0.75 | KDM4E (0.51) | ALDH1A1KDM4EKMT2AACE2KLKB1 | |
| SCHEMBL23059522 | 0.75 | ALDH1A1 (0.50) | ALDH1A1KDM4EKMT2AACE2KLKB1 | |
| SCHEMBL22358618 | 0.73 | ALDH1A1 (0.49) | ALDH1A1KDM4EKMT2AACE2KLKB1 | |
| SCHEMBL26547011 | 0.73 | CNR1 (0.61) | ALDH1A1HTR2AKMT2AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605486-B2 | Afibrotic compounds, devices, and uses thereof | SIGILON THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20250235409-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. | 2025-07-24 | — | — | US | disclosed |
| US-12161760-B2 | Implantable particles and related methods | SIGILON THERAPEUTICS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20230123802-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY | SIGILON THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230123802-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY | SIGILON THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20220267794-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR TREATING FABRY DISEASE | SIGILON THERAPEUTICS, INC. | 2022-08-25 | — | — | US | disclosed |
| EP-3946463-A1 | COMPOSITIONS, DEVICES AND METHODS FOR FACTOR VII THERAPY | Sigilon Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20210145889-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | SIGILON THERAPEUTICS, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20210145889-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | SIGILON THERAPEUTICS, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20210145759-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. | 2021-05-20 | — | — | US | disclosed |
| WO-2020198695-A1 | COMPOSITIONS, DEVICES AND METHODS FOR FACTOR VII THERAPY | SIGILON THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020198695-A1 | COMPOSITIONS, DEVICES AND METHODS FOR FACTOR VII THERAPY | SIGILON THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| US-20200263196-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | SIGILON THERAPEUTICS, INC. | 2020-08-20 | — | — | US | disclosed |
| US-20200263196-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | SIGILON THERAPEUTICS, INC. | 2020-08-20 | — | — | US | disclosed |
| EP-3687580-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | Sigilon Therapeutics, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| WO-2019195056-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | SIGILON THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019195056-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | SIGILON THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019195055-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019195055-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019067766-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | SIGILON THERAPEUTICS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267794-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR TREATING FABRY DISEASE | GLA, GAA, GBA1 | ALDH1A1 2310/4885KDM4E 4287/4885HTR2A 4769/4885 |
| US-20210145759-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | TNNT2, TNNI3, TNNC1 | ALDH1A1 408/4885KDM4E 4731/4885HTR2A 4622/4885 |
| US-12161760-B2 | Implantable particles and related methods | TNNT2, TNNI3, TNNC1 | ALDH1A1 408/4885KDM4E 4731/4885HTR2A 4622/4885 |
| US-20210145889-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | MSI2, CXCL12, SOST | ALDH1A1 738/4885KDM4E 4145/4885HTR2A 3950/4885 |
| US-20250235409-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | TNNT2, TNNI3, TNNC1 | ALDH1A1 408/4885KDM4E 4731/4885HTR2A 4622/4885 |
| US-20230123802-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY | F7, F13B, F9 | ALDH1A1 2464/4885KDM4E 4003/4885HTR2A 3462/4885 |
| US-12605486-B2 | Afibrotic compounds, devices, and uses thereof | SLC11A2, ARG1, COL2A1 | ALDH1A1 553/4885KDM4E 2867/4885HTR2A 2727/4885 |
| US-20200263196-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | ALDH1A2, MYOC, PDE6C | ALDH1A1 834/4885KDM4E 4407/4885HTR2A 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.